Browse PDGFD

Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Note=Released by platelets upon wounding.
Domain PF00431 CUB domain
PF00341 PDGF/VEGF domain
Function

Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays an important role in wound healing. Induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Can initiate events that lead to a mesangial proliferative glomerulonephritis, including influx of monocytes and macrophages and production of extracellular matrix (By similarity).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001101 response to acid chemical
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002691 regulation of cellular extravasation
GO:0002693 positive regulation of cellular extravasation
GO:0006979 response to oxidative stress
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010035 response to inorganic substance
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030335 positive regulation of cell migration
GO:0031952 regulation of protein autophosphorylation
GO:0031954 positive regulation of protein autophosphorylation
GO:0032103 positive regulation of response to external stimulus
GO:0032835 glomerulus development
GO:0033002 muscle cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035696 monocyte extravasation
GO:0036119 response to platelet-derived growth factor
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0040017 positive regulation of locomotion
GO:0042542 response to hydrogen peroxide
GO:0043200 response to amino acid
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0045123 cellular extravasation
GO:0045860 positive regulation of protein kinase activity
GO:0046777 protein autophosphorylation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0060326 cell chemotaxis
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0070301 cellular response to hydrogen peroxide
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071670 smooth muscle cell chemotaxis
GO:0071671 regulation of smooth muscle cell chemotaxis
GO:0071673 positive regulation of smooth muscle cell chemotaxis
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072012 glomerulus vasculature development
GO:0072109 glomerular mesangium development
GO:0072110 glomerular mesangial cell proliferation
GO:0072111 cell proliferation involved in kidney development
GO:0072124 regulation of glomerular mesangial cell proliferation
GO:0072126 positive regulation of glomerular mesangial cell proliferation
GO:0090183 regulation of kidney development
GO:0090184 positive regulation of kidney development
GO:0090192 regulation of glomerulus development
GO:0090193 positive regulation of glomerulus development
GO:0097529 myeloid leukocyte migration
GO:1901342 regulation of vasculature development
GO:1901722 regulation of cell proliferation involved in kidney development
GO:1901724 positive regulation of cell proliferation involved in kidney development
GO:1904018 positive regulation of vasculature development
GO:2000147 positive regulation of cell motility
GO:2000437 regulation of monocyte extravasation
GO:2000439 positive regulation of monocyte extravasation
Molecular Function GO:0005161 platelet-derived growth factor receptor binding
GO:0008083 growth factor activity
GO:0070851 growth factor receptor binding
Cellular Component GO:0005788 endoplasmic reticulum lumen
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04540 Gap junction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-162582: Signal Transduction
R-HSA-186797: Signaling by PDGF
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDGFD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDGFD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDGFD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1680.0138
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6440.552
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.560.0933
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1230.822
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5650.657
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4360.781
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0330.938
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1070.932
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1240.933
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7720.581
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.1060.251
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.230.116
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDGFD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.212.59.70.602
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDGFD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDGFD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDGFD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDGFD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDGFD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDGFD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDGFD
Nameplatelet derived growth factor D
Aliases SCDGF-B; MSTP036; IEGF; spinal cord derived growth factor B; SCDGFB; PDGF-D; iris-expressed growth factor; s ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDGFD collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PDGFD.
ID Name Drug Type Targets #Targets
DB05139CR002BiotechPDGFD1
DB05465TandutinibSmall MoleculeFLT3, PDGFD2